Ara Metjian, MD
Associate Professor, Medicine-Hematology

Photo
Medical School:
  • MD, Drexel University College of Medicine (2001)
Undergraduate School:
  • BA, Bucknell University (PA) (1995)
Internship:
  • University of North Carolina at Chapel Hill Program (2001)
Residency:
  • University of North Carolina at Chapel Hill Program, Internal Medicine (1999)
Fellowships:
  • University of Pennsylvania Program, Hematology and Oncology (2005)
  • Duke University Hospital Program, Hematology (2008)
Department: Medicine-Hematology

Professional Titles

  • Associate Professor

Research Interests

I have an active interest in all aspects of Benign Hematology, particularly in congenital bleeding disorders and acquired diseases of hemostasis, such as thrombotic microangiopathies and immune-mediated cytopenias. These conditions are rare and often occur in under-represented populations, which makes their research and development even more necessary. By offering a wide array of clinical trials for these disease states, we can move care forward and offer improved therapies

Publications

  • Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv. 2024 Feb 13;8(3):620-623. PubMed PMID: 38100454
  • Metjian A. iTTP: more long-term consequences. Blood. 2023 Jan 19;141(3):216-217. PubMed PMID: 36656614
  • Tarantino MD, Hardesty B, Metjian A, Ortel TL, Chen J, Badejo K, Ma A, Cuker A, Rajasekhar A, Friedman KD, Janbain M. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study. Haemophilia. 2023 Sep;29(5):1259-1268. PubMed PMID: 37584309
  • Metjian A. iTTP: more long-term consequences. Blood. 2023 Jan 19;141(3):216-217. PubMed PMID: 36656614
  • Scully M, de la Rubia J, Pavenski K, Metjian A, Knöbl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022 Dec;20(12):2810-2822. PubMed PMID: 36138517
  • Shah H, Chen H, Pan XZ, Metjian A, Brodsky RA, Braunstein EM, Chaturvedi S. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv. 2022 Dec 13;6(23):6071-6074. PubMed PMID: 35914225
  • Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA. Race, rituximab, and relapse in TTP. Blood. 2022 Sep 22;140(12):1335-1344. PubMed PMID: 35797471
  • Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella PC, Metjian A, Fasano RM, Music-Aplenc L. Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study. Transfusion. 2022 Feb;62(2):396-405. PubMed PMID: 34931321
  • Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella PC, Metjian A, Fasano RM, Music-Aplenc L. Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study. Transfusion. 2021 Dec 20. [Epub ahead of print] PubMed PMID: 34931321
  • Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021 Apr 27;5(8):2137-2141. PubMed PMID: 33881463
  • Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020 Dec;221:108616. PubMed PMID: 33148511
  • Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. PubMed PMID: 32095224
  • Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 Feb;18(2):479-484. PubMed PMID: 31691462
View All (13 Total) View Less

Professional Memberships

  • American Society of Hematology, Member
  • American Society for Apheresis, Member
  • International Society of Thrombosis and Hemostasis, Member

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Hematology, Board Certification
Conditions & Treatments
  • Blood / Lymphatic System - Bleeding Disorders
  • Blood / Lymphatic System
  • Blood / Lymphatic System - Blood Disorders
  • Blood / Lymphatic System - Clotting Disorders
Care Philosophy
In order to provide the best-level of care, exquisite attention to detail is needed, as there are many factors that are often overlooked or disregarded in patients with bleeding or thrombotic disorders. I strive to know these facts about a patient's history so that clinically relevant information is not missed.

Public Speaking
Yes
I have been invited to speak on local, regional, and national levels, to both physicians, as well as patients. This includes invitations from Physician Offices, Schools, Pharmaceutical Companies, and national and international physician organizations.

General Information

Medical Schools:
  • MD, Drexel University College of Medicine (2001)
Undergraduate Schools:
  • BA, Bucknell University (PA) (1995)
Internships:
  • University of North Carolina at Chapel Hill Program (2001)
Residency Programs:
  • University of North Carolina at Chapel Hill Program, Internal Medicine (1999)
Fellowships:
  • University of Pennsylvania Program, Hematology and Oncology (2005)
  • Duke University Hospital Program, Hematology (2008)
Department: Medicine-Hematology
SOM Resources
CU Resources
Contact Us
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;